Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio, Inc. (IMA) filed its Q3 2025 10‑Q and reported a transformative quarter driven by a reverse recapitalization with Ikena Oncology and a concurrent PIPE financing. The company ended September 30, 2025 with cash, cash equivalents and marketable securities of $142.6 million, positioning it to fund operations for at least the next 12 months.
For the quarter, ImageneBio recorded a net loss of $24.8 million, reflecting research and development expense of $15.6 million and general and administrative expense of $11.0 million as it advances its lead program, IMG‑007, a non‑depleting anti‑OX40 monoclonal antibody. For the nine months ended September 30, 2025, net loss totaled $38.4 million.
The July 25, 2025 reverse recapitalization brought in Ikena’s net assets (including $54.6 million of cash and $40.1 million of marketable securities) and the company raised additional capital via a 2,508,339‑share PIPE for approximately $75.0 million gross. A related $22.5 million pre‑merger term loan was forgiven at closing. ImageneBio also completed a Non‑OX40 divestiture, recording a related $7.5 million promissory note receivable and an offsetting CVR liability of $7.5 million. Shares outstanding were 11,181,672 as of November 3, 2025.
ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results through a press release dated November 12, 2025, which is included as an exhibit to the report.
The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the federal securities laws. ImageneBio’s common stock trades on The Nasdaq Capital Market under the symbol IMA.
ImageneBio, Inc. (IMA) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership effective 11/01/2025, indicating no securities are beneficially owned. The filing was made by one reporting person, and includes an Exhibit 24 Power of Attorney authorizing the attorney-in-fact to sign on the reporting person’s behalf.
This is a routine disclosure establishing the insider’s baseline ownership at the time they became subject to reporting.
ImageneBio filed a Rule 424(b)(3) prospectus supplement to its Form S-1, relating to the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement updates the prospectus with information from a Current Report on Form 8-K. The company’s common stock trades on Nasdaq as “IMA,” and the last reported sales price was $8.24 per share on November 4, 2025.
The attached 8-K reports the Board increased its authorized size from six to seven directors and appointed Joseph P. Slattery to the Board effective November 1, 2025, and as Chair of the Audit Committee effective November 18, 2025. The company entered into its standard indemnification agreement with Mr. Slattery.
ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025. He will serve as Chair of the Audit Committee effective November 18, 2025.
The company entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to its Form S-1.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale of 2,508,337 shares of common stock by selling stockholders. The supplement updates the base prospectus with recent disclosures and attaches three Current Reports on Form 8‑K.
- On October 10, 2025, CFO and principal financial officer Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025; the resignation was not due to any disagreement.
- On October 21, 2025, the board appointed CEO Kristin Yarema, Ph.D., as interim principal financial officer, effective immediately.
- On October 23, 2025, the company elected not to automatically renew a transition services agreement with Miragene Inc. and extended a subset of services for six months; total fees for the extension services are $200,000.
The company’s common stock trades on Nasdaq as “IMA.” On October 29, 2025, the last reported sale price was $8.79 per share.
Imagenebio, Inc. (IMA) filed an 8-K stating it will not allow its transition services agreement with Miragene Inc. to automatically renew and will instead extend a subset of services for six months after the initial term. The Miragene Extension Services include chemistry, manufacturing and controls, as well as translational sciences research and support. Total fees payable to Miragene for the extension are $200,000, reflecting a limited, short-term continuation of select operational support.
ImageneBio, Inc. appointed its Chief Executive Officer, Kristin Yarema, Ph.D., as the company’s interim principal financial officer, effective immediately on October 21, 2025.
The board made the appointment to fill the finance leadership role on an interim basis. Dr. Yarema’s biographical information is incorporated by reference from the “Management” section of the company’s Form S-1 (File No. 333-290108) filed on September 8, 2025.
ImageneBio, Inc. reported that its Chief Financial Officer and principal financial officer, Jotin Marango, M.D., Ph.D., has submitted his resignation, effective October 20, 2025. The company states that his resignation is not due to any disagreement with the company. ImageneBio plans to conduct a search for a new chief financial officer to fill the role.
ImageneBio, Inc. reported that director Stephen Hui Wang acquired common stock on
The report discloses that the Form 4 was filed late due to delays obtaining EDGAR codes. The filing describes the chain of ownership: shares were received in exchange for Series C-1 and C-2 preferred shares of Legacy Inmagene, and voting/investment power over the reported holdings is exercised by Mr. Wang through HLC GP and affiliated entities.